{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T23:45:24Z","timestamp":1780789524712,"version":"3.54.1"},"reference-count":193,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40257-026-01027-0","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:46:56Z","timestamp":1774972016000},"page":"515-535","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Corrective and Restorative Dermatology in Cancer Survivors: An Urgent Unmet Need!"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4029-941X","authenticated-orcid":false,"given":"Luca","family":"Rapparini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timila Assia","family":"Touhouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Fattore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azael","family":"Freites-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Hirtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Apalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Vigarios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Maret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Starace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Sibaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"1027_CR1","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40257-022-00705-z","volume":"23","author":"AS Bang","year":"2022","unstructured":"Bang AS, Anadkat MJ, Choi JN, LeBoeuf NR, Jung JY, Markova A, et al. Oncodermatology: advancing the science and care of cancer patients and survivors. Am J Clin Dermatol. 2022;23:587\u20139. https:\/\/doi.org\/10.1007\/s40257-022-00705-z.","journal-title":"Am J Clin Dermatol"},{"key":"1027_CR2","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/S0140-6736(22)00242-2","volume":"399","author":"J Emery","year":"2022","unstructured":"Emery J, Butow P, Lai-Kwon J, Nekhlyudov L, Rynderman M, Jefford M. Management of common clinical problems experienced by survivors of cancer. Lancet. 2022;399:1537\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(22)00242-2.","journal-title":"Lancet"},{"key":"1027_CR3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.jaad.2020.08.005","volume":"85","author":"AM Rossi","year":"2021","unstructured":"Rossi AM, Hibler BP, Navarrete-Dechent C, Lacouture ME. Restorative oncodermatology: diagnosis and management of dermatologic sequelae from cancer therapies. J Am Acad Dermatol. 2021;85:693\u2013707. https:\/\/doi.org\/10.1016\/j.jaad.2020.08.005.","journal-title":"J Am Acad Dermatol"},{"key":"1027_CR4","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1200\/JCO.2011.39.3611","volume":"30","author":"KE Kinahan","year":"2012","unstructured":"Kinahan KE, Sharp LK, Seidel K, Leisenring W, Didwania A, Lacouture ME, et al. Scarring, disfigurement, and quality of life in long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2012;30:2466\u201374. https:\/\/doi.org\/10.1200\/JCO.2011.39.3611.","journal-title":"J Clin Oncol"},{"key":"1027_CR5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.36849\/JDD.2020.5040","volume":"19","author":"L Aizman","year":"2020","unstructured":"Aizman L, Nelson K, Sparks AD, Friedman AJ. The influence of supportive oncodermatology interventions on patient quality of life: a cross-sectional survey. J Drugs Dermatol. 2020;19:477\u201382.","journal-title":"J Drugs Dermatol"},{"key":"1027_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-024-08407-4","volume":"32","author":"M Starace","year":"2024","unstructured":"Starace M, Rapparini L, Cedirian S, Evangelista V, Pampaloni F, Bruni F, et al. Management of cutaneous adverse events caused by antineoplastic therapies: a single-center experience. Support Care Cancer. 2024;32:200. https:\/\/doi.org\/10.1007\/s00520-024-08407-4.","journal-title":"Support Care Cancer"},{"key":"1027_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s11764-009-0091-4","volume":"3","author":"KE Kinahan","year":"2009","unstructured":"Kinahan KE, Gandhi M, Lacouture ME, Eilers R, Haryani A, Didwania A, et al. Dermatologic issues in adult survivors of childhood cancer. J Cancer Surviv. 2009;3:158\u201363. https:\/\/doi.org\/10.1007\/s11764-009-0091-4.","journal-title":"J Cancer Surviv"},{"key":"1027_CR8","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1001\/jamadermatol.2020.1795","volume":"156","author":"Z Yu","year":"2020","unstructured":"Yu Z, Dee EC, Bach DQ, Mostaghimi A, LeBoeuf NR. Evaluation of a comprehensive skin toxicity program for patients treated with epidermal growth factor receptor inhibitors at a cancer treatment center. JAMA Dermatol. 2020;156:1079\u201385. https:\/\/doi.org\/10.1001\/jamadermatol.2020.1795.","journal-title":"JAMA Dermatol"},{"key":"1027_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16111960","volume":"16","author":"M Starace","year":"2024","unstructured":"Starace M, Rapparini L, Cedirian S. Skin malignancies due to anti-cancer therapies. Cancers (Basel). 2024;16:1960. https:\/\/doi.org\/10.3390\/cancers16111960.","journal-title":"Cancers (Basel)"},{"key":"1027_CR10","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1111\/jdv.70021","volume":"39","author":"A Freites-Martinez","year":"2025","unstructured":"Freites-Martinez A, Apalla Z, Shapiro J, Iorizzo M, Rudnicka L, Lo Sicco K, et al. Expert consensus for prevention, diagnosis and management of persistent chemotherapy-induced alopecia. J Eur Acad Dermatol Venereol. 2025;39:2039\u201346. https:\/\/doi.org\/10.1111\/jdv.70021.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1027_CR11","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s13555-025-01378-2","volume":"15","author":"M Starace","year":"2025","unstructured":"Starace M, Mandel VD, Ardigo M, Carpanese MA, Quadrelli F, Pampaloni F, et al. Defining predictive factors for permanent chemotherapy-induced alopecia: trichoscopy, reflectance confocal microscopy and histopathology study on 77 patients. Dermatol Ther (Heidelb). 2025;15:869\u201387. https:\/\/doi.org\/10.1007\/s13555-025-01378-2.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1027_CR12","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.jaad.2018.03.056","volume":"80","author":"A Freites-Martinez","year":"2019","unstructured":"Freites-Martinez A, Shapiro J, van den Hurk C, Goldfarb S, Jimenez JJ, Rossi AM, et al. Hair disorders in cancer survivors. J Am Acad Dermatol. 2019;80:1199\u2013213. https:\/\/doi.org\/10.1016\/j.jaad.2018.03.056.","journal-title":"J Am Acad Dermatol"},{"key":"1027_CR13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/DAD.0b013e3181fcfc25","volume":"33","author":"M Miteva","year":"2011","unstructured":"Miteva M, Misciali C, Fanti PA, Vincenzi C, Romanelli P, Tosti A. Permanent alopecia after systemic chemotherapy: a clinicopathological study of 10 cases. Am J Dermatopathol. 2011;33:345\u201350. https:\/\/doi.org\/10.1097\/DAD.0b013e3181fcfc25.","journal-title":"Am J Dermatopathol"},{"key":"1027_CR14","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1016\/S1470-2045(12)70553-3","volume":"14","author":"R Paus","year":"2013","unstructured":"Paus R, Haslam IS, Sharov AA, Botchkarev VA. Pathobiology of chemotherapy-induced hair loss. Lancet Oncol. 2013;14:e50-59. https:\/\/doi.org\/10.1016\/S1470-2045(12)70553-3.","journal-title":"Lancet Oncol"},{"key":"1027_CR15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/jocd.12687","volume":"18","author":"A Rossi","year":"2019","unstructured":"Rossi A, Caterina Fortuna M, Caro G, Cardone M, Garelli V, Grassi S, et al. Monitoring chemotherapy\u2010induced alopecia with trichoscopy. J Cosmet Dermatol. 2019;18:575\u201380. https:\/\/doi.org\/10.1111\/jocd.12687.","journal-title":"J Cosmet Dermatol"},{"key":"1027_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00520-025-09664-7","volume":"33","author":"AE Smith","year":"2025","unstructured":"Smith AE, Harrison M, McNeil C, Beith J, Lim J. Assessment of long-term alopecia after adjuvant taxane therapy for early breast cancer: a cross-sectional survey. Support Care Cancer. 2025;33:615. https:\/\/doi.org\/10.1007\/s00520-025-09664-7.","journal-title":"Support Care Cancer"},{"key":"1027_CR17","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamadermatol.2021.3676","volume":"157","author":"B Bhoyrul","year":"2021","unstructured":"Bhoyrul B, Asfour L, Lutz G, Mitchell L, Jerjen R, Sinclair RD, et al. Clinicopathologic characteristics and response to treatment of persistent chemotherapy-induced alopecia in breast cancer survivors. JAMA Dermatol. 2021;157:1335\u201342. https:\/\/doi.org\/10.1001\/jamadermatol.2021.3676.","journal-title":"JAMA Dermatol"},{"key":"1027_CR18","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1634\/theoncologist.2018-0184","volume":"24","author":"D Kang","year":"2019","unstructured":"Kang D, Kim I-R, Choi E-K, Im YH, Park YH, Ahn JS, et al. Permanent chemotherapy-induced alopecia in patients with breast cancer: a 3-year prospective cohort study. Oncologist. 2019;24:414\u201320. https:\/\/doi.org\/10.1634\/theoncologist.2018-0184.","journal-title":"Oncologist"},{"key":"1027_CR19","doi-asserted-by":"publisher","first-page":"e170","DOI":"10.1016\/j.clbc.2024.09.008","volume":"25","author":"SK Premji","year":"2025","unstructured":"Premji SK, Ruddy KJ, Vierkant RA, Larson N, Loprinzi C, Dulmage B, et al. Perceptions of delayed alopecia among breast cancer survivors. Clin Breast Cancer. 2025;25:e170\u20137. https:\/\/doi.org\/10.1016\/j.clbc.2024.09.008.","journal-title":"Clin Breast Cancer"},{"key":"1027_CR20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10549-013-2744-2","volume":"142","author":"L Gallicchio","year":"2013","unstructured":"Gallicchio L, Calhoun C, Helzlsouer KJ. Aromatase inhibitor therapy and hair loss among breast cancer survivors. Breast Cancer Res Treat. 2013;142:435\u201343. https:\/\/doi.org\/10.1007\/s10549-013-2744-2.","journal-title":"Breast Cancer Res Treat"},{"key":"1027_CR21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0190-9622(96)90500-9","volume":"35","author":"M Duvic","year":"1996","unstructured":"Duvic M, Lemak NA, Valero V, Hymes SR, Farmer KL, Hortobagyi GN, et al. A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol. 1996;35:74\u20138. https:\/\/doi.org\/10.1016\/S0190-9622(96)90500-9.","journal-title":"J Am Acad Dermatol"},{"key":"1027_CR22","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1303a152","volume":"13","author":"M Iorizzo","year":"2023","unstructured":"Iorizzo M, Wa\u015bkiel-Burnat A, Anedda J, Piraccini BM, Apalla Z, Rudnicka L, et al. Persistent chemotherapy-induced alopecia treated with low dose oral Minoxidil: a multicenter retrospective case series of 15 patients. Dermatol Pract Concept. 2023;13:e2023152. https:\/\/doi.org\/10.5826\/dpc.1303a152.","journal-title":"Dermatol Pract Concept"},{"key":"1027_CR23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10549-024-07440-5","volume":"208","author":"AM-S Kuo","year":"2024","unstructured":"Kuo AM-S, Reingold RE, Ketosugbo KF, Pan A, Kraehenbuehl L, Dusza S, et al. Oral minoxidil for late alopecia in cancer survivors. Breast Cancer Res Treat. 2024;208:491\u20139. https:\/\/doi.org\/10.1007\/s10549-024-07440-5.","journal-title":"Breast Cancer Res Treat"},{"key":"1027_CR24","doi-asserted-by":"publisher","unstructured":"Girnita A, Bjerring P, Llado Grove G, Kauppi S, Andriessen A, Lynde C, et al. A practical algorithm for the prevention and treatment of cutaneous side effects of hormonal cancer therapy. J Drugs Dermatol. 2025;24:49631s3\u201310. https:\/\/doi.org\/10.36849\/JDD.49631.","DOI":"10.36849\/JDD.49631"},{"key":"1027_CR25","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jaad.2024.02.030","volume":"90","author":"RC Hill","year":"2024","unstructured":"Hill RC, Wang Y, Shaikh B, Lipner SR. No increased risk of breast or gynecologic malignancies in women exposed to spironolactone for dermatologic conditions: a retrospective cohort study. J Am Acad Dermatol. 2024;90:1302\u20134. https:\/\/doi.org\/10.1016\/j.jaad.2024.02.030.","journal-title":"J Am Acad Dermatol"},{"key":"1027_CR26","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamadermatol.2021.5866","volume":"158","author":"K Bommareddy","year":"2022","unstructured":"Bommareddy K, Hamade H, Lopez-Olivo MA, Wehner M, Tosh T, Barbieri JS. Association of Spironolactone use with risk of cancer: a systematic review and meta-analysis. JAMA Dermatol. 2022;158:275\u201382. https:\/\/doi.org\/10.1001\/jamadermatol.2021.5866.","journal-title":"JAMA Dermatol"},{"key":"1027_CR27","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1111\/bjd.13443","volume":"172","author":"DA Glaser","year":"2015","unstructured":"Glaser DA, Hossain P, Perkins W, Griffiths T, Ahluwalia G, Weng E, et al. Long-term safety and efficacy of bimatoprost solution 0\u00b703% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial. Br J Dermatol. 2015;172:1384\u201394. https:\/\/doi.org\/10.1111\/bjd.13443.","journal-title":"Br J Dermatol"},{"key":"1027_CR28","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000004755","author":"A Rossi","year":"2025","unstructured":"Rossi A, Pan A, Menzer C, Lavin L, Aleissa S, Aleisa A, et al. Platelet-rich plasma treatment for endocrine-induced alopecia and persistent chemotherapy-induced alopecia in breast cancer survivors: a randomized, controlled, pilot study. Dermatol Surg. 2025. https:\/\/doi.org\/10.1097\/DSS.0000000000004755.","journal-title":"Dermatol Surg"},{"key":"1027_CR29","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.abd.2020.03.005","volume":"95","author":"GB de Silva","year":"2020","unstructured":"de Silva GB, Ciccolini K, Donati A, van den Hurk C. Scalp cooling to prevent chemotherapy-induced alopecia. An Bras Dermatol. 2020;95:631\u20137. https:\/\/doi.org\/10.1016\/j.abd.2020.03.005.","journal-title":"An Bras Dermatol"},{"key":"1027_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-025-07858-5","volume":"215","author":"CA Kearney","year":"2025","unstructured":"Kearney CA, Brinks AL, Needle CD, Adhikari S, Marks DK, Shapiro J, et al. Adverse effects of scalp cooling for the reduction of chemotherapy-induced alopecia: a systematic review and meta-analysis. Breast Cancer Res Treat. 2025;215:11. https:\/\/doi.org\/10.1007\/s10549-025-07858-5.","journal-title":"Breast Cancer Res Treat"},{"key":"1027_CR31","doi-asserted-by":"publisher","first-page":"5709","DOI":"10.3390\/curroncol31090423","volume":"31","author":"AM Perez","year":"2024","unstructured":"Perez AM, Haberland NI, Miteva M, Wikramanayake TC. Chemotherapy-induced alopecia by Docetaxel: prevalence, treatment and prevention. Curr Oncol. 2024;31:5709\u201321. https:\/\/doi.org\/10.3390\/curroncol31090423.","journal-title":"Curr Oncol"},{"key":"1027_CR32","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1001\/jamadermatol.2018.3465","volume":"154","author":"DH Marks","year":"2018","unstructured":"Marks DH, Qureshi A, Friedman A. Evaluation of prevention interventions for Taxane-Induced dermatologic adverse events: a systematic review. JAMA Dermatol. 2018;154:1465\u201372. https:\/\/doi.org\/10.1001\/jamadermatol.2018.3465.","journal-title":"JAMA Dermatol"},{"key":"1027_CR33","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10549-018-4855-2","volume":"171","author":"M Mart\u00edn","year":"2018","unstructured":"Mart\u00edn M, de la Torre-Montero JC, L\u00f3pez-Tarruella S, Pinilla K, Casado A, Fernandez S, et al. Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling. Breast Cancer Res Treat. 2018;171:627\u201334. https:\/\/doi.org\/10.1007\/s10549-018-4855-2.","journal-title":"Breast Cancer Res Treat"},{"key":"1027_CR34","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1003a74","volume":"10","author":"A Rossi","year":"2020","unstructured":"Rossi A, Caro G, Fortuna MC, Pigliacelli F, D\u2019Arino A, Carlesimo M. Prevention and treatment of chemotherapy-induced alopecia. Dermatol Pract Concept. 2020;10:e2020074. https:\/\/doi.org\/10.5826\/dpc.1003a74.","journal-title":"Dermatol Pract Concept"},{"key":"1027_CR35","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1177\/13591053221075503","volume":"27","author":"A Versluis","year":"2022","unstructured":"Versluis A, van Alphen K, Dercksen W, de Haas H, Kaptein AA, van den Hurk C. Looking bad: female patients drawing their representation of chemotherapy-induced alopecia. J Health Psychol. 2022;27:3013\u201327. https:\/\/doi.org\/10.1177\/13591053221075503.","journal-title":"J Health Psychol"},{"key":"1027_CR36","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1007\/s00520-021-06748-y","volume":"30","author":"A Versluis","year":"2022","unstructured":"Versluis A, van Alphen K, Dercksen W, de Haas H, van den Hurk C, Kaptein AA. \u201cDear hair loss\u201d-illness perceptions of female patients with chemotherapy-induced alopecia. Support Care Cancer. 2022;30:3955\u201363. https:\/\/doi.org\/10.1007\/s00520-021-06748-y.","journal-title":"Support Care Cancer"},{"key":"1027_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31432","volume":"72","author":"EJ Kim","year":"2025","unstructured":"Kim EJ, Hlobik M, Berbert L, Brace-O\u2019Neill J, Vrooman L, Huang JT. Impact of persistent alopecia on quality of life in childhood cancer and transplant survivors. Pediatr Blood Cancer. 2025;72:e31432. https:\/\/doi.org\/10.1002\/pbc.31432.","journal-title":"Pediatr Blood Cancer"},{"key":"1027_CR38","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/jamadermatol.2018.0454","volume":"154","author":"A Freites-Martinez","year":"2018","unstructured":"Freites-Martinez A, Shapiro J, Chan D, Fornier M, Modi S, Gajria D, et al. Endocrine therapy-induced alopecia in patients with breast cancer. JAMA Dermatol. 2018;154:670\u20135. https:\/\/doi.org\/10.1001\/jamadermatol.2018.0454.","journal-title":"JAMA Dermatol"},{"key":"1027_CR39","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.annder.2022.11.013","volume":"150","author":"V Sibaud","year":"2023","unstructured":"Sibaud V, Sollena P. Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: an updated review for clinical practice. Ann Dermatol Venereol. 2023;150:208\u201312. https:\/\/doi.org\/10.1016\/j.annder.2022.11.013.","journal-title":"Ann Dermatol Venereol"},{"key":"1027_CR40","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.jaad.2020.05.081","volume":"83","author":"C Wei","year":"2020","unstructured":"Wei C, Bovonratwet P, Gu A, Moawad G, Silverberg JI, Friedman AJ. Spironolactone use does not increase the risk of female breast cancer recurrence: a retrospective analysis. J Am Acad Dermatol. 2020;83:1021\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2020.05.081.","journal-title":"J Am Acad Dermatol"},{"key":"1027_CR41","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1001\/jamadermatol.2020.2127","volume":"156","author":"GS Phillips","year":"2020","unstructured":"Phillips GS, Freret ME, Friedman DN, Trelles S, Kukoyi O, Freites-Martinez A, et al. Assessment and treatment outcomes of persistent radiation-induced alopecia in patients with cancer. JAMA Dermatol. 2020;156:963\u201372. https:\/\/doi.org\/10.1001\/jamadermatol.2020.2127.","journal-title":"JAMA Dermatol"},{"key":"1027_CR42","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jaad.2018.03.055","volume":"80","author":"A Freites-Martinez","year":"2019","unstructured":"Freites-Martinez A, Shapiro J, Goldfarb S, Nangia J, Jimenez JJ, Paus R, et al. Hair disorders in patients with cancer. J Am Acad Dermatol. 2019;80:1179\u201396. https:\/\/doi.org\/10.1016\/j.jaad.2018.03.055.","journal-title":"J Am Acad Dermatol"},{"key":"1027_CR43","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/pon.4039","volume":"26","author":"P Dua","year":"2017","unstructured":"Dua P, Heiland MF, Kracen AC, Deshields TL. Cancer-related hair loss: a selective review of the alopecia research literature. Psychooncology. 2017;26:438\u201343. https:\/\/doi.org\/10.1002\/pon.4039.","journal-title":"Psychooncology"},{"key":"1027_CR44","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","volume":"19","author":"ME Lacouture","year":"2011","unstructured":"Lacouture ME, Anadkat MJ, Bensadoun R-J, Bryce J, Chan A, Epstein JB, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19:1079\u201395. https:\/\/doi.org\/10.1007\/s00520-011-1197-6.","journal-title":"Support Care Cancer"},{"key":"1027_CR45","doi-asserted-by":"publisher","first-page":"e745","DOI":"10.1111\/jdv.20569","volume":"39","author":"M Starace","year":"2025","unstructured":"Starace M, Rapparini L, Cedirian S, Quadrelli F, Pampaloni F, Bruni F, et al. Erosive pustular dermatosis of the scalp due to EGFR inhibitors: a multicentric study by EADV task force of \u201cDermatology for Cancer Patients.\u201d J Eur Acad Dermatol Venereol. 2025;39:e745\u20139. https:\/\/doi.org\/10.1111\/jdv.20569.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1027_CR46","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1097\/CAD.0000000000001494","volume":"34","author":"J Nowaczyk","year":"2023","unstructured":"Nowaczyk J, Fret K, Kaminska-Winciorek G, Rudnicka L, Czuwara J. EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines. Anticancer Drugs. 2023;34:942\u20138. https:\/\/doi.org\/10.1097\/CAD.0000000000001494.","journal-title":"Anticancer Drugs"},{"key":"1027_CR47","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/14782715231196606","volume":"53","author":"S Gupta","year":"2023","unstructured":"Gupta S, Chopra D, Preeyati. Erosive pustular dermatosis of the scalp secondary to Erlotinib: a rare occurrence with trichoscopic perspective. J R Coll Physicians Edinb. 2023;53:255\u20137. https:\/\/doi.org\/10.1177\/14782715231196606.","journal-title":"J R Coll Physicians Edinb"},{"key":"1027_CR48","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jaad.2016.12.016","volume":"76","author":"M Starace","year":"2017","unstructured":"Starace M, Loi C, Bruni F, Alessandrini A, Misciali C, Patrizi A, et al. Erosive pustular dermatosis of the scalp: clinical, trichoscopic, and histopathologic features of 20 cases. J Am Acad Dermatol. 2017;76:1109\u20131114.e2. https:\/\/doi.org\/10.1016\/j.jaad.2016.12.016.","journal-title":"J Am Acad Dermatol"},{"key":"1027_CR49","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1303a180","volume":"13","author":"M Starace","year":"2023","unstructured":"Starace M, Piraccini BM, Carpanese MA, Iorizzo M, Apalla Z. Folliculitis-decalvans like alopecia during treatment with EGFR inhibitors for lung cancer: a case series of 6 patients. Dermatol Pract Concept. 2023;13:e2023180. https:\/\/doi.org\/10.5826\/dpc.1303a180.","journal-title":"Dermatol Pract Concept"},{"key":"1027_CR50","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/ijd.14744","volume":"59","author":"KH Lee","year":"2020","unstructured":"Lee KH, Carley SK, Kraus CN, Mesinkovska NA. Treatment of erosive pustular dermatosis: a systematic review of the literature. Int J Dermatol. 2020;59:770\u201386. https:\/\/doi.org\/10.1111\/ijd.14744.","journal-title":"Int J Dermatol"},{"key":"1027_CR51","doi-asserted-by":"publisher","unstructured":"Nazzaro G, Giacalone S, Bortoluzzi P, Veraldi S, Marzano AV. Erosive pustular dermatosis of the scalp induced by gefitinib: case and review of the literature. Dermatol Online J. 2021;27(2):13030\/qt8w87m82r. https:\/\/doi.org\/10.5070\/D3272052385.","DOI":"10.5070\/D3272052385"},{"key":"1027_CR52","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/j.1365-2133.2006.07452.x","volume":"155","author":"ME Lacouture","year":"2006","unstructured":"Lacouture ME, Lai SE. The PRIDE (Papulopustules and\/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome. Br J Dermatol. 2006;155:852\u20134. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07452.x.","journal-title":"Br J Dermatol"},{"key":"1027_CR53","first-page":"799","volume":"10","author":"F Al-Niaimi","year":"2011","unstructured":"Al-Niaimi F, Lyon C. Tamoxifen-induced hirsutism. J Drugs Dermatol. 2011;10:799\u2013801.","journal-title":"J Drugs Dermatol"},{"key":"1027_CR54","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2174\/157488606777934477","volume":"1","author":"BM Piraccini","year":"2006","unstructured":"Piraccini BM, Iorizzo M, Rech G, Tosti A. Drug-induced hair disorders. Curr Drug Saf. 2006;1:301\u20135. https:\/\/doi.org\/10.2174\/157488606777934477.","journal-title":"Curr Drug Saf"},{"key":"1027_CR55","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000315499","volume":"221","author":"M Lapidoth","year":"2010","unstructured":"Lapidoth M, Dierickx C, Lanigan S, Paasch U, Campo-Voegeli A, Dahan S, et al. Best practice options for hair removal in patients with unwanted facial hair using combination therapy with laser: guidelines drawn up by an expert working group. Dermatology. 2010;221:34\u201342. https:\/\/doi.org\/10.1159\/000315499.","journal-title":"Dermatology"},{"key":"1027_CR56","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1016\/j.jaad.2009.11.589","volume":"63","author":"T Vergou","year":"2010","unstructured":"Vergou T, Stratigos AJ, Karapanagiotou EM, Matekovits AE, Dilana KD, Tsimboukis S, et al. Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib. J Am Acad Dermatol. 2010;63:e56\u201358. https:\/\/doi.org\/10.1016\/j.jaad.2009.11.589.","journal-title":"J Am Acad Dermatol"},{"key":"1027_CR57","doi-asserted-by":"publisher","first-page":"418","DOI":"10.5114\/ada.2017.71106","volume":"34","author":"W Owczarek","year":"2017","unstructured":"Owczarek W, S\u0142owi\u0144ska M, Lesiak A, Ci\u0105\u017cy\u0144ska M, Maci\u0105g A, Paluchowska E, et al. The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors. Postepy Dermatol Alergol. 2017;34:418\u201328. https:\/\/doi.org\/10.5114\/ada.2017.71106.","journal-title":"Postepy Dermatol Alergol"},{"key":"1027_CR58","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1001\/jamadermatol.2017.0500","volume":"153","author":"S B\u00e9trian","year":"2017","unstructured":"B\u00e9trian S, Gomez-Roca C, Vigarios E, Delord JP, Sibaud V. Severe onycholysis and eyelash trichomegaly following use of new selective Pan-FGFR inhibitors. JAMA Dermatol. 2017;153:723\u20135. https:\/\/doi.org\/10.1001\/jamadermatol.2017.0500.","journal-title":"JAMA Dermatol"},{"key":"1027_CR59","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1007\/s13555-024-01263-4","volume":"14","author":"M Starace","year":"2024","unstructured":"Starace M, Cedirian S, Rapparini L, Bruni F, Piraccini BM. Vorasidenib-induced trichomegaly and hypertrichosis: a new side effect in a patient with diffuse Astrocytoma. Dermatol Ther (Heidelb). 2024;14:2917\u201321. https:\/\/doi.org\/10.1007\/s13555-024-01263-4.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1027_CR60","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jaad.2014.07.032","volume":"72","author":"JB Macdonald","year":"2015","unstructured":"Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane. J Am Acad Dermatol. 2015;72:203\u201318. https:\/\/doi.org\/10.1016\/j.jaad.2014.07.032. (quiz 219\u201320).","journal-title":"J Am Acad Dermatol"},{"key":"1027_CR61","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/DSS.0000000000001131","volume":"44","author":"BY Yan","year":"2019","unstructured":"Yan BY, Hibler BP, Connolly KL, Rossi AM. Intraoral laser hair removal of a palate free flap: tips and technique. Dermatol Surg. 2019;44:122\u20134. https:\/\/doi.org\/10.1097\/DSS.0000000000001131.","journal-title":"Dermatol Surg"},{"key":"1027_CR62","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1111\/j.1365-4632.2007.03270.x","volume":"46","author":"J Jackson","year":"2007","unstructured":"Jackson J, Caro JJ, Caro G, Garfield F, Huber F, Zhou W, et al. The effect of eflornithine 13.9% cream on the bother and discomfort due to hirsutism. Int J Dermatol. 2007;46:976\u201381. https:\/\/doi.org\/10.1111\/j.1365-4632.2007.03270.x.","journal-title":"Int J Dermatol"},{"key":"1027_CR63","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70040","author":"M Iorizzo","year":"2025","unstructured":"Iorizzo M, Pampaloni F, Apalla Z, Elshot Y, Bruni F, Cedirian S, et al. Nail toxicities associated with cancer therapies: Insights and recommendations from the EADV task force dermatology for cancer patients. J Eur Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.70040.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1027_CR64","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4103\/ijd.ijd_723_22","volume":"69","author":"M Trivedi","year":"2024","unstructured":"Trivedi M, Mehta RD, Ghiya BC, Soni P. Impact of chemotherapy-induced nail changes on quality of life: a cross-sectional study from a tertiary care centre. Indian J Dermatol. 2024;69:205\u201311. https:\/\/doi.org\/10.4103\/ijd.ijd_723_22.","journal-title":"Indian J Dermatol"},{"key":"1027_CR65","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.det.2007.01.006","volume":"25","author":"BM Piraccini","year":"2007","unstructured":"Piraccini BM, Iorizzo M. Drug reactions affecting the nail unit: diagnosis and management. Dermatol Clin. 2007;25:215\u201321. https:\/\/doi.org\/10.1016\/j.det.2007.01.006.","journal-title":"Dermatol Clin"},{"key":"1027_CR66","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2165\/00128071-200304010-00004","volume":"4","author":"BM Piraccini","year":"2003","unstructured":"Piraccini BM, Iorizzo M, Tosti A. Drug-induced nail abnormalities. Am J Clin Dermatol. 2003;4:31\u20137. https:\/\/doi.org\/10.2165\/00128071-200304010-00004.","journal-title":"Am J Clin Dermatol"},{"key":"1027_CR67","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.jaad.2025.01.069","volume":"92","author":"EN Axler","year":"2025","unstructured":"Axler EN, Iorizzo M, McLellan B, Lipner SR. Nail toxicity associated with anticancer agents. J Am Acad Dermatol. 2025;92:1327\u201336. https:\/\/doi.org\/10.1016\/j.jaad.2025.01.069.","journal-title":"J Am Acad Dermatol"},{"key":"1027_CR68","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1016\/S1470-2045(14)71133-7","volume":"16","author":"C Robert","year":"2015","unstructured":"Robert C, Sibaud V, Mateus C, Verschoore M, Charles C, Lanoy E, et al. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol. 2015;16:e181\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(14)71133-7.","journal-title":"Lancet Oncol"},{"key":"1027_CR69","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4103\/ijd.IJD_37_19","volume":"65","author":"N Saraswat","year":"2020","unstructured":"Saraswat N, Sood A, Verma R, Kumar D, Kumar S. Nail changes induced by chemotherapeutic agents. Indian J Dermatol. 2020;65:193\u20138. https:\/\/doi.org\/10.4103\/ijd.IJD_37_19.","journal-title":"Indian J Dermatol"},{"key":"1027_CR70","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1046\/j.1468-3083.2003.00774.x","volume":"17","author":"E Ghetti","year":"2003","unstructured":"Ghetti E, Piraccini B, Tosti A. Onycholysis and subungual haemorrhages secondary to systemic chemotherapy (paclitaxel). Acad Dermatol Venereol. 2003;17:459\u201360. https:\/\/doi.org\/10.1046\/j.1468-3083.2003.00774.x.","journal-title":"Acad Dermatol Venereol"},{"key":"1027_CR71","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1684\/ejd.2016.2833","volume":"26","author":"V Sibaud","year":"2016","unstructured":"Sibaud V, Leb\u0153uf NR, Roche H, Belum VR, Gladieff L, Deslandres M, et al. Dermatological adverse events with taxane chemotherapy. Eur J Dermatol. 2016;26:427\u201343. https:\/\/doi.org\/10.1684\/ejd.2016.2833.","journal-title":"Eur J Dermatol"},{"key":"1027_CR72","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.clindermatol.2013.06.015","volume":"31","author":"A Shemer","year":"2013","unstructured":"Shemer A, Daniel CR. Common nail disorders. Clin Dermatol. 2013;31:578\u201386. https:\/\/doi.org\/10.1016\/j.clindermatol.2013.06.015.","journal-title":"Clin Dermatol"},{"key":"1027_CR73","doi-asserted-by":"publisher","unstructured":"Emvalomati A, Oflidou V, Papageorgiou C, Kemanetzi C, Giannouli M, Kalloniati E, et al. Narrative review of drug-associated nail toxicities in oncologic patients. Dermatol Pract Concept. 2023;13(1):e2023064. https:\/\/doi.org\/10.5826\/dpc.1301a64.","DOI":"10.5826\/dpc.1301a64"},{"key":"1027_CR74","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.1200\/JCO.2005.15.651","volume":"23","author":"F Scott\u00e9","year":"2005","unstructured":"Scott\u00e9 F, Tourani J-M, Banu E, Peyromaure M, Levy E, Marsan S, et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol. 2005;23:4424\u20139. https:\/\/doi.org\/10.1200\/JCO.2005.15.651.","journal-title":"J Clin Oncol"},{"key":"1027_CR75","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s10549-017-4268-7","volume":"164","author":"J-Y Kim","year":"2017","unstructured":"Kim J-Y, Ok ON, Seo J-J, Lee S-H, Ahn JS, Im Y-H, et al. A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant\/adjuvant docetaxel chemotherapy. Breast Cancer Res Treat. 2017;164:617\u201325. https:\/\/doi.org\/10.1007\/s10549-017-4268-7.","journal-title":"Breast Cancer Res Treat"},{"key":"1027_CR76","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13555-019-00338-x","volume":"10","author":"MA Chessa","year":"2020","unstructured":"Chessa MA, Iorizzo M, Richert B, L\u00f3pez-Estebaranz JL, Rigopoulos D, Tosti A, et al. Pathogenesis, clinical signs and treatment recommendations in brittle nails: a review. Dermatol Ther (Heidelb). 2020;10:15\u201327. https:\/\/doi.org\/10.1007\/s13555-019-00338-x.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1027_CR77","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1684\/ejd.2016.2747","volume":"26","author":"E Dika","year":"2016","unstructured":"Dika E, Patrizi A, Ribero S, Fanti PA, Starace M, Melotti B, et al. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma. Eur J Dermatol. 2016;26:232\u20139. https:\/\/doi.org\/10.1684\/ejd.2016.2747.","journal-title":"Eur J Dermatol"},{"key":"1027_CR78","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40257-021-00645-0","volume":"23","author":"E Raschi","year":"2022","unstructured":"Raschi E, Fusaroli M, La Placa M, Ardizzoni A, Zamagni C, Poluzzi E, et al. Skin toxicities with cyclin-dependent kinase 4\/6 inhibitors in breast cancer: signals from disproportionality analysis of the FDA adverse event reporting system. Am J Clin Dermatol. 2022;23:247\u201355. https:\/\/doi.org\/10.1007\/s40257-021-00645-0.","journal-title":"Am J Clin Dermatol"},{"key":"1027_CR79","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.det.2014.12.001","volume":"33","author":"M Iorizzo","year":"2015","unstructured":"Iorizzo M. Tips to treat the 5 most common nail disorders: brittle nails, onycholysis, paronychia, psoriasis, onychomycosis. Dermatol Clin. 2015;33:175\u201383. https:\/\/doi.org\/10.1016\/j.det.2014.12.001.","journal-title":"Dermatol Clin"},{"key":"1027_CR80","doi-asserted-by":"publisher","unstructured":"Piraccini BM, Rapparini L. Treatment of nail fragility in males and females. Textbook of cosmetic dermatology. 6th ed. Boca Raton: CRC Press; 2024. p. 225\u20137. https:\/\/doi.org\/10.1201\/b22897-23.","DOI":"10.1201\/b22897-23"},{"key":"1027_CR81","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","volume":"19","author":"M Lacouture","year":"2018","unstructured":"Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19:31\u20139. https:\/\/doi.org\/10.1007\/s40257-018-0384-3.","journal-title":"Am J Clin Dermatol"},{"key":"1027_CR82","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/ijd.15740","volume":"61","author":"MK Gupta","year":"2022","unstructured":"Gupta MK, Lipner SR. Review of chemotherapy-associated paronychia. Int J Dermatol. 2022;61:410\u20135. https:\/\/doi.org\/10.1111\/ijd.15740.","journal-title":"Int J Dermatol"},{"key":"1027_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2022.12.024","volume":"90","author":"E Baumrin","year":"2024","unstructured":"Baumrin E, Loren AW, Falk SJ, Mays JW, Cowen EW. Chronic graft-versus-host disease. Part I: epidemiology, pathogenesis, and clinical manifestations. J Am Acad Dermatol. 2024;90:1\u201316. https:\/\/doi.org\/10.1016\/j.jaad.2022.12.024.","journal-title":"J Am Acad Dermatol"},{"key":"1027_CR84","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/jdv.15357","volume":"33","author":"A Szlauer-Stefa\u0144ska","year":"2019","unstructured":"Szlauer-Stefa\u0144ska A, Kami\u0144ska-Winciorek G, Giebel S. Onychoscopy of non-infectious nail abnormalities in patients after allogeneic haematopoietic stem cell transplantation. J Eur Acad Dermatol Venereol. 2019;33:637\u201342. https:\/\/doi.org\/10.1111\/jdv.15357.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1027_CR85","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jaad.2022.01.051","volume":"88","author":"RF Wang","year":"2023","unstructured":"Wang RF, Ko D, Friedman BJ, Lim HW, Mohammad TF. Disorders of hyperpigmentation. Part I. Pathogenesis and clinical features of common pigmentary disorders. J Am Acad Dermatol. 2023;88:271\u201388. https:\/\/doi.org\/10.1016\/j.jaad.2022.01.051.","journal-title":"J Am Acad Dermatol"},{"key":"1027_CR86","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s40257-020-00519-x","volume":"21","author":"KA Ashack","year":"2020","unstructured":"Ashack KA, Kuritza V, Visconti MJ, Ashack L. Dermatologic sequelae associated with radiation therapy. Am J Clin Dermatol. 2020;21:541\u201355. https:\/\/doi.org\/10.1007\/s40257-020-00519-x.","journal-title":"Am J Clin Dermatol"},{"key":"1027_CR87","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00520-004-0697-z","volume":"13","author":"BK Mohanti","year":"2005","unstructured":"Mohanti BK, Bansal M. Late sequelae of radiotherapy in adults. Support Care Cancer. 2005;13:775\u201380. https:\/\/doi.org\/10.1007\/s00520-004-0697-z.","journal-title":"Support Care Cancer"},{"key":"1027_CR88","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/j.1468-3083.2012.04680.x","volume":"27","author":"S Vano-Galvan","year":"2013","unstructured":"Vano-Galvan S, Fernandez-Lizarbe E, Truchuelo M, Diaz-Ley B, Grillo E, Sanchez V, et al. Dynamic skin changes of acute radiation dermatitis revealed by in vivo reflectance confocal microscopy. J Eur Acad Dermatol Venereol. 2013;27:1143\u201350. https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04680.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1027_CR89","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.jaad.2017.06.044","volume":"77","author":"J Dai","year":"2017","unstructured":"Dai J, Belum VR, Wu S, Sibaud V, Lacouture ME. Pigmentary changes in patients treated with targeted anticancer agents: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77:902\u2013910.e2. https:\/\/doi.org\/10.1016\/j.jaad.2017.06.044.","journal-title":"J Am Acad Dermatol"},{"key":"1027_CR90","first-page":"158","volume":"68","author":"LK Gupta","year":"2002","unstructured":"Gupta LK, Tanwar RK, Khare AK, Jain SK. Bleomycin induced flagellate pigmentation. Indian J Dermatol Venereol Leprol. 2002;68:158\u20139.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"1027_CR91","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1177\/1078155215580468","volume":"22","author":"A Vennepureddy","year":"2016","unstructured":"Vennepureddy A, Siddique MN, Odaimi M, Terjanian T. Bleomycin-induced flagellate erythema in a patient with Hodgkin\u2019s lymphoma\u2014a case report and review of literature. J Oncol Pharm Pract. 2016;22:556\u201360. https:\/\/doi.org\/10.1177\/1078155215580468.","journal-title":"J Oncol Pharm Pract"},{"key":"1027_CR92","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1684\/ejd.2017.3180","volume":"27","author":"I Hern\u00e1ndez-Arag\u00fc\u00e9s","year":"2017","unstructured":"Hern\u00e1ndez-Arag\u00fc\u00e9s I, Baniandr\u00e9s-Rodr\u00edguez O, Vilas-Boas PT, Conde-Montero E, Su\u00e1rez-Fern\u00e1ndez R. Cutaneous drug reactions: chemotherapy-induced hyperpigmentation. Eur J Dermatol. 2017;27:679\u201380. https:\/\/doi.org\/10.1684\/ejd.2017.3180.","journal-title":"Eur J Dermatol"},{"key":"1027_CR93","doi-asserted-by":"publisher","first-page":"763","DOI":"10.36849\/JDD.2020.4887","volume":"19","author":"A Shenoy","year":"2020","unstructured":"Shenoy A, Madan R. Post-inflammatory hyperpigmentation: a review of treatment strategies. J Drugs Dermatol. 2020;19:763\u20138. https:\/\/doi.org\/10.36849\/JDD.2020.4887.","journal-title":"J Drugs Dermatol"},{"key":"1027_CR94","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMicm1909329","volume":"382","author":"JK Schaefer","year":"2020","unstructured":"Schaefer JK, Ramnath N. Fluorouracil-induced hyperpigmentation. N Engl J Med. 2020;382:e6. https:\/\/doi.org\/10.1056\/NEJMicm1909329.","journal-title":"N Engl J Med"},{"key":"1027_CR95","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1159\/000439047","volume":"231","author":"M Masson Regnault","year":"2015","unstructured":"Masson Regnault M, Gadaud N, Boulinguez S, Tournier E, Lamant L, Gladieff L, et al. Chemotherapy-related reticulate hyperpigmentation: a case series and review of the literature. Dermatology. 2015;231:312\u20138. https:\/\/doi.org\/10.1159\/000439047.","journal-title":"Dermatology"},{"key":"1027_CR96","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/pon.3038","volume":"22","author":"P Brunault","year":"2013","unstructured":"Brunault P, Suzanne I, Trzepidur-Edom M, Garaud P, Calais G, Toledano A, et al. Depression is associated with some patient-perceived cosmetic changes, but not with radiotherapy-induced late toxicity, in long-term breast cancer survivors. Psychooncology. 2013;22:590\u20137. https:\/\/doi.org\/10.1002\/pon.3038.","journal-title":"Psychooncology"},{"key":"1027_CR97","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.jaad.2021.11.026","volume":"87","author":"RE Reingold","year":"2022","unstructured":"Reingold RE, Corbett BE, Blank NR, Day RA, McManus MJ, Ma J, et al. Quality of life before and after treatment of cutaneous metastases with palliative radiotherapy. J Am Acad Dermatol. 2022;87:868\u201370. https:\/\/doi.org\/10.1016\/j.jaad.2021.11.026.","journal-title":"J Am Acad Dermatol"},{"key":"1027_CR98","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s11136-017-1526-4","volume":"26","author":"J Lee","year":"2017","unstructured":"Lee J, Park W, Choi DH, Huh SJ, Kim I-R, Kang D, et al. Patient-reported symptoms of radiation dermatitis during breast cancer radiotherapy: a pilot study. Qual Life Res. 2017;26:1713\u20139. https:\/\/doi.org\/10.1007\/s11136-017-1526-4.","journal-title":"Qual Life Res"},{"key":"1027_CR99","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jaad.2017.01.036","volume":"77","author":"S Chaowattanapanit","year":"2017","unstructured":"Chaowattanapanit S, Silpa-Archa N, Kohli I, Lim HW, Hamzavi I. Postinflammatory hyperpigmentation: a comprehensive overview: treatment options and prevention. J Am Acad Dermatol. 2017;77:607\u201321. https:\/\/doi.org\/10.1016\/j.jaad.2017.01.036.","journal-title":"J Am Acad Dermatol"},{"key":"1027_CR100","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28124839","volume":"28","author":"AM Thawabteh","year":"2023","unstructured":"Thawabteh AM, Jibreen A, Karaman D, Thawabteh A, Karaman R. Skin pigmentation types, causes and treatment\u2014a review. Molecules. 2023;28:4839. https:\/\/doi.org\/10.3390\/molecules28124839.","journal-title":"Molecules"},{"key":"1027_CR101","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jamadermatol.2016.4399","volume":"153","author":"O Agbai","year":"2017","unstructured":"Agbai O, Hamzavi I, Jagdeo J. Laser treatments for postinflammatory hyperpigmentation: a systematic review. JAMA Dermatol. 2017;153:199\u2013206. https:\/\/doi.org\/10.1001\/jamadermatol.2016.4399.","journal-title":"JAMA Dermatol"},{"key":"1027_CR102","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","volume":"19","author":"V Sibaud","year":"2018","unstructured":"Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol. 2018;19:345\u201361. https:\/\/doi.org\/10.1007\/s40257-017-0336-3.","journal-title":"Am J Clin Dermatol"},{"key":"1027_CR103","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","volume":"83","author":"AN Geisler","year":"2020","unstructured":"Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020;83:1255\u201368. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.132.","journal-title":"J Am Acad Dermatol"},{"key":"1027_CR104","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/bjd.21781","volume":"187","author":"VA Nikolaou","year":"2022","unstructured":"Nikolaou VA, Apalla Z, Carrera C, Fattore D, Sollena P, Riganti J, et al. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients. Br J Dermatol. 2022;187:962\u20139. https:\/\/doi.org\/10.1111\/bjd.21781.","journal-title":"Br J Dermatol"},{"key":"1027_CR105","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/jdv.17855","volume":"36","author":"Z Apalla","year":"2022","unstructured":"Apalla Z, Nikolaou V, Fattore D, Fabbrocini G, Freites-Martinez A, Sollena P, et al. European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force \u201cDermatology for cancer patients\u201d position statement. J Eur Acad Dermatol Venereol. 2022;36:332\u201350. https:\/\/doi.org\/10.1111\/jdv.17855.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1027_CR106","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1001\/jamadermatol.2024.5136","volume":"161","author":"M Starace","year":"2025","unstructured":"Starace M, Cedirian S, Rapparini L, Pileri A, Carrera C, Giavedoni P, et al. Immune checkpoint inhibitor-induced vitiligo-like depigmentation. JAMA Dermatol. 2025;161:216\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2024.5136.","journal-title":"JAMA Dermatol"},{"key":"1027_CR107","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","volume":"152","author":"C Hua","year":"2016","unstructured":"Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with Pembrolizumab. JAMA Dermatol. 2016;152:45\u201351. https:\/\/doi.org\/10.1001\/jamadermatol.2015.2707.","journal-title":"JAMA Dermatol"},{"key":"1027_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143658","volume":"15","author":"P Sollena","year":"2023","unstructured":"Sollena P, Vasiliki N, Kotteas E, Stratigos AJ, Fattore D, Orlandi A, et al. Cyclin-Dependent Kinase 4\/6 inhibitors and dermatologic adverse events: results from the EADV Task Force \u201cDermatology for Cancer Patients\u201d international study. Cancers Basel. 2023;15:3658. https:\/\/doi.org\/10.3390\/cancers15143658.","journal-title":"Cancers Basel"},{"key":"1027_CR109","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ctrv.2017.07.003","volume":"59","author":"P Strojan","year":"2017","unstructured":"Strojan P, Hutcheson KA, Eisbruch A, Beitler JJ, Langendijk JA, Lee AWM, et al. Treatment of late sequelae after radiotherapy for head and neck cancer. Cancer Treat Rev. 2017;59:79\u201392. https:\/\/doi.org\/10.1016\/j.ctrv.2017.07.003.","journal-title":"Cancer Treat Rev"},{"key":"1027_CR110","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70149","author":"D Fattore","year":"2025","unstructured":"Fattore D, Apalla Z, Freites-Martinez A, Tommasino N, Nikolaou V, Lauletta G, et al. Prevention and management of cutaneous immune-related adverse events: EADV Task Force statement. J Eur Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.70149.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1027_CR111","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1111\/jdv.20809","volume":"39","author":"KA Papp","year":"2025","unstructured":"Papp KA, Puig L, Beecker J, Chandran V, Claveau J, Cort\u00e9s J, et al. Systemic treatment of immune checkpoint inhibitor-induced psoriasis: inference-based guidance. J Eur Acad Dermatol Venereol. 2025;39:1881\u201394. https:\/\/doi.org\/10.1111\/jdv.20809.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1027_CR112","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41409-023-02181-3","volume":"59","author":"Z Hudda","year":"2024","unstructured":"Hudda Z, Flannery A, Teusink-Cross A, Davies SM, Khandelwal P. Topical ruxolitinib is promising as sole or adjunctive therapy in treating maculopapular rash of acute and chronic skin GVHD. Bone Marrow Transplant. 2024;59:425\u20137. https:\/\/doi.org\/10.1038\/s41409-023-02181-3.","journal-title":"Bone Marrow Transplant"},{"key":"1027_CR113","doi-asserted-by":"publisher","first-page":"e378","DOI":"10.1111\/jdv.20379","volume":"39","author":"K Ezzedine","year":"2025","unstructured":"Ezzedine K, Wolkerstorfer A, Wei S, Korba AA, Kornacki D, Rosmarin D. Incidence of nonmelanoma skin cancer in patients with vitiligo who applied ruxolitinib cream. J Eur Acad Dermatol Venereol. 2025;39:e378\u201380. https:\/\/doi.org\/10.1111\/jdv.20379.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1027_CR114","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40257-023-00840-1","volume":"25","author":"W Hu","year":"2024","unstructured":"Hu W, Thornton M, Livingston RA. Real-world use of Ruxolitinib cream: safety analysis at 1\u00a0year. Am J Clin Dermatol. 2024;25:327\u201332. https:\/\/doi.org\/10.1007\/s40257-023-00840-1.","journal-title":"Am J Clin Dermatol"},{"key":"1027_CR115","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/bjd.21852","volume":"187","author":"BN Wilson","year":"2022","unstructured":"Wilson BN, Shah R, Menzer C, Aleisa A, Sun MD, Kwong BY, et al. Consensus on the clinical management of chronic radiation dermatitis and radiation fibrosis: a Delphi survey. Br J Dermatol. 2022;187:1054\u20136. https:\/\/doi.org\/10.1111\/bjd.21852.","journal-title":"Br J Dermatol"},{"key":"1027_CR116","doi-asserted-by":"publisher","first-page":"269","DOI":"10.21037\/apm-24-158","volume":"14","author":"MA Chakraborty","year":"2025","unstructured":"Chakraborty MA, Lee SF, Wong HCY, Tse SSW, Chan AW, Kwan JYY, et al. Chronic radiation dermatitis in breast cancer patients: pathophysiology, prevention and management strategies, and clinical impact. Ann Palliat Med. 2025;14:269\u201382. https:\/\/doi.org\/10.21037\/apm-24-158.","journal-title":"Ann Palliat Med"},{"key":"1027_CR117","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ejca.2006.11.016","volume":"43","author":"AFS Galimont-Collen","year":"2007","unstructured":"Galimont-Collen AFS, Vos LE, Lavrijsen APM, Ouwerkerk J, Gelderblom H. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer. 2007;43:845\u201351. https:\/\/doi.org\/10.1016\/j.ejca.2006.11.016.","journal-title":"Eur J Cancer"},{"key":"1027_CR118","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1093\/annonc\/mdu533","volume":"26","author":"V Sibaud","year":"2015","unstructured":"Sibaud V, Vigarios E, Combemale P, Lamant L, Lacouture ME, Lacaze JL, et al. T-DM1-related telangiectasias: a potential role in secondary bleeding events. Ann Oncol. 2015;26:436\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdu533.","journal-title":"Ann Oncol"},{"key":"1027_CR119","first-page":"34","volume":"7","author":"AM Rossi","year":"2014","unstructured":"Rossi AM, Nehal KS, Lee EH. Radiation-induced breast telangiectasias treated with the pulsed dye laser. J Clin Aesthet Dermatol. 2014;7:34\u20137.","journal-title":"J Clin Aesthet Dermatol"},{"key":"1027_CR120","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/lsm.22780","volume":"50","author":"AM Rossi","year":"2018","unstructured":"Rossi AM, Blank NR, Nehal K, Dusza S, Lee EH. Effect of laser therapy on quality of life in patients with radiation-induced breast telangiectasias. Lasers Surg Med. 2018;50:284\u201390. https:\/\/doi.org\/10.1002\/lsm.22780.","journal-title":"Lasers Surg Med"},{"key":"1027_CR121","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ijwd.2019.10.003","volume":"5","author":"MN Ferreira","year":"2019","unstructured":"Ferreira MN, Ramseier JY, Leventhal JS. Dermatologic conditions in women receiving systemic cancer therapy. Int J Womens Dermatol. 2019;5:285\u2013307. https:\/\/doi.org\/10.1016\/j.ijwd.2019.10.003.","journal-title":"Int J Womens Dermatol"},{"key":"1027_CR122","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.critrevonc.2008.09.004","volume":"70","author":"SG Mohile","year":"2009","unstructured":"Mohile SG, Mustian K, Bylow K, Hall W, Dale W. Management of complications of androgen deprivation therapy in the older man. Crit Rev Oncol Hematol. 2009;70:235\u201355. https:\/\/doi.org\/10.1016\/j.critrevonc.2008.09.004.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1027_CR123","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jaad.2016.12.031","volume":"77","author":"A Sadeghian","year":"2017","unstructured":"Sadeghian A, Rouhana H, Oswald-Stumpf B, Boh E. Etiologies and management of cutaneous flushing: nonmalignant causes. J Am Acad Dermatol. 2017;77:391\u2013402. https:\/\/doi.org\/10.1016\/j.jaad.2016.12.031.","journal-title":"J Am Acad Dermatol"},{"key":"1027_CR124","first-page":"186","volume":"23","author":"P LoRusso","year":"2009","unstructured":"LoRusso P. Toward evidence-based management of the dermatologic effects of EGFR inhibitors. Oncology (Williston Park). 2009;23:186\u201394.","journal-title":"Oncology (Williston Park)"},{"key":"1027_CR125","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.jaad.2004.08.039","volume":"53","author":"G Hall","year":"2005","unstructured":"Hall G, Phillips TJ. Estrogen and skin: the effects of estrogen, menopause, and hormone replacement therapy on the skin. J Am Acad Dermatol. 2005;53:555\u201368. https:\/\/doi.org\/10.1016\/j.jaad.2004.08.039.","journal-title":"J Am Acad Dermatol"},{"key":"1027_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/cells13181524","volume":"13","author":"A Olivieri","year":"2024","unstructured":"Olivieri A, Mancini G. Current approaches for the prevention and treatment of acute and chronic GVHD. Cells. 2024;13:1524. https:\/\/doi.org\/10.3390\/cells13181524.","journal-title":"Cells"},{"key":"1027_CR127","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40257-016-0185-5","volume":"17","author":"RR Riahi","year":"2016","unstructured":"Riahi RR, Bush AE, Cohen PR. Topical retinoids: therapeutic mechanisms in the treatment of photodamaged skin. Am J Clin Dermatol. 2016;17:265\u201376. https:\/\/doi.org\/10.1007\/s40257-016-0185-5.","journal-title":"Am J Clin Dermatol"},{"key":"1027_CR128","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/pon.1006","volume":"15","author":"CS Carver","year":"2006","unstructured":"Carver CS, Smith RG, Petronis VM, Antoni MH. Quality of life among long-term survivors of breast cancer: different types of antecedents predict different classes of outcomes. Psychooncology. 2006;15:749\u201358. https:\/\/doi.org\/10.1002\/pon.1006.","journal-title":"Psychooncology"},{"key":"1027_CR129","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1159\/000513241","volume":"16","author":"M Dieterich","year":"2021","unstructured":"Dieterich M, Allmendinger S, Gerber B, Reimer T, Hartmann S, Stachs A, et al. Prevalence, clinical significance and risk factors for developing scar pain and sensibility disorders in breast cancer patients after breast-conserving therapy and mastectomy. Breast Care (Basel). 2021;16:507\u201315. https:\/\/doi.org\/10.1159\/000513241.","journal-title":"Breast Care (Basel)"},{"key":"1027_CR130","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jaad.2019.07.084","volume":"82","author":"RG Micheletti","year":"2020","unstructured":"Micheletti RG, Chansky PB, Haun PL, Seykora JT, Dekerlegand J, Sultan LR, et al. Ablative fractional laser resurfacing for treatment of sclerosis and contractures in chronic graft-versus-host disease: a pilot study. J Am Acad Dermatol. 2020;82:984\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2019.07.084.","journal-title":"J Am Acad Dermatol"},{"key":"1027_CR131","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1007\/s00520-013-1896-2","volume":"21","author":"RKS Wong","year":"2013","unstructured":"Wong RKS, Bensadoun R-J, Boers-Doets CB, Bryce J, Chan A, Epstein JB, et al. Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Support Care Cancer. 2013;21:2933\u201348. https:\/\/doi.org\/10.1007\/s00520-013-1896-2.","journal-title":"Support Care Cancer"},{"key":"1027_CR132","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40257-022-00744-6","volume":"24","author":"FS Frech","year":"2023","unstructured":"Frech FS, Hernandez L, Urbonas R, Zaken GA, Dreyfuss I, Nouri K. Hypertrophic scars and keloids: advances in treatment and review of established therapies. Am J Clin Dermatol. 2023;24:225\u201345. https:\/\/doi.org\/10.1007\/s40257-022-00744-6.","journal-title":"Am J Clin Dermatol"},{"key":"1027_CR133","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/lsm.22120","volume":"45","author":"JS Waibel","year":"2013","unstructured":"Waibel JS, Wulkan AJ, Shumaker PR. Treatment of hypertrophic scars using laser and laser assisted corticosteroid delivery. Lasers Surg Med. 2013;45:135\u201340. https:\/\/doi.org\/10.1002\/lsm.22120.","journal-title":"Lasers Surg Med"},{"key":"1027_CR134","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/s12885-019-5553-0","volume":"19","author":"J Gass","year":"2019","unstructured":"Gass J, Mitchell S, Hanna M. How do breast cancer surgery scars impact survivorship? Findings from a nationwide survey in the United States. BMC Cancer. 2019;19:342. https:\/\/doi.org\/10.1186\/s12885-019-5553-0.","journal-title":"BMC Cancer"},{"key":"1027_CR135","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s10549-018-4790-2","volume":"170","author":"A Voci","year":"2018","unstructured":"Voci A, Lee D, Ho E, Crane-Okada R, DiNome M. Impact of port site scar on perception of patients with breast cancer: patient-reported outcomes. Breast Cancer Res Treat. 2018;170:569\u201372. https:\/\/doi.org\/10.1007\/s10549-018-4790-2.","journal-title":"Breast Cancer Res Treat"},{"key":"1027_CR136","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00403-019-01957-2","volume":"311","author":"TS Vaidya","year":"2019","unstructured":"Vaidya TS, Mori S, Dusza SW, Rossi AM, Nehal KS, Lee EH. Appearance-related psychosocial distress following facial skin cancer surgery using the FACE-Q Skin Cancer. Arch Dermatol Res. 2019;311:691\u20136. https:\/\/doi.org\/10.1007\/s00403-019-01957-2.","journal-title":"Arch Dermatol Res"},{"key":"1027_CR137","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/DSS.0000000000000253","volume":"41","author":"JF Sobanko","year":"2015","unstructured":"Sobanko JF, Sarwer DB, Zvargulis Z, Miller CJ. Importance of physical appearance in patients with skin cancer. Dermatol Surg. 2015;41:183\u20138. https:\/\/doi.org\/10.1097\/DSS.0000000000000253.","journal-title":"Dermatol Surg"},{"key":"1027_CR138","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jaad.2025.03.022","volume":"93","author":"IJ Veldhuizen","year":"2025","unstructured":"Veldhuizen IJ, Dusza SW, Kuo A, Aleisa A, Blue E, Adhikari S, et al. Patient-reported quality of life and aesthetic satisfaction continues to improve for 1-year after Mohs surgery: a multicenter prospective cohort study. J Am Acad Dermatol. 2025;93:444\u201350. https:\/\/doi.org\/10.1016\/j.jaad.2025.03.022.","journal-title":"J Am Acad Dermatol"},{"key":"1027_CR139","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.fsc.2019.07.013","volume":"27","author":"PG Lee","year":"2019","unstructured":"Lee PG, Kerolus JL. Management of surgical scars. Facial Plast Surg Clin North Am. 2019;27:513\u20137. https:\/\/doi.org\/10.1016\/j.fsc.2019.07.013.","journal-title":"Facial Plast Surg Clin North Am"},{"key":"1027_CR140","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/tbj.13044","volume":"24","author":"O Kaidar-Person","year":"2018","unstructured":"Kaidar-Person O, Marks LB, Jones EL. Pentoxifylline and vitamin E for treatment or prevention of radiation-induced fibrosis in patients with breast cancer. Breast J. 2018;24:816\u20139. https:\/\/doi.org\/10.1111\/tbj.13044.","journal-title":"Breast J"},{"key":"1027_CR141","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.bjoms.2016.11.323","volume":"55","author":"V Patel","year":"2017","unstructured":"Patel V, McGurk M. Use of pentoxifylline and tocopherol in radiation-induced fibrosis and fibroatrophy. Br J Oral Maxillofac Surg. 2017;55:235\u201341. https:\/\/doi.org\/10.1016\/j.bjoms.2016.11.323.","journal-title":"Br J Oral Maxillofac Surg"},{"key":"1027_CR142","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1007\/s00520-022-06829-6","volume":"30","author":"S Finkelstein","year":"2022","unstructured":"Finkelstein S, Kanee L, Behroozian T, Wolf JR, van den Hurk C, Chow E, et al. Comparison of clinical practice guidelines on radiation dermatitis: a narrative review. Support Care Cancer. 2022;30:4663\u201374. https:\/\/doi.org\/10.1007\/s00520-022-06829-6.","journal-title":"Support Care Cancer"},{"key":"1027_CR143","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3322\/caac.21157","volume":"62","author":"JB Epstein","year":"2012","unstructured":"Epstein JB, Thariat J, Bensadoun R-J, Barasch A, Murphy BA, Kolnick L, et al. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin. 2012;62:400\u201322. https:\/\/doi.org\/10.3322\/caac.21157.","journal-title":"CA Cancer J Clin"},{"key":"1027_CR144","doi-asserted-by":"publisher","DOI":"10.3390\/dj12010017","volume":"12","author":"S Al-Ansari","year":"2024","unstructured":"Al-Ansari S, Stolze J, Bresters D, Brook AH, Laheij AMGA, Brand HS, et al. Late complications in long-term childhood cancer survivors: what the oral health professional needs to know. Dent J (Basel). 2024;12:17. https:\/\/doi.org\/10.3390\/dj12010017.","journal-title":"Dent J (Basel)"},{"key":"1027_CR145","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.critrevonc.2016.03.012","volume":"102","author":"M Buglione","year":"2016","unstructured":"Buglione M, Cavagnini R, Di Rosario F, Maddalo M, Vassalli L, Grisanti S, et al. Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: xerostomia and trismus (Part 2). Literature review and consensus statement. Crit Rev Oncol Hematol. 2016;102:47\u201354. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.03.012.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1027_CR146","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejca.2017.03.006","volume":"78","author":"S H\u00f8xbroe Michaelsen","year":"2017","unstructured":"H\u00f8xbroe Michaelsen S, Gr\u00f8nh\u00f8j C, H\u00f8xbroe Michaelsen J, Friborg J, von Buchwald C. Quality of life in survivors of oropharyngeal cancer: a systematic review and meta-analysis of 1366 patients. Eur J Cancer. 2017;78:91\u2013102. https:\/\/doi.org\/10.1016\/j.ejca.2017.03.006.","journal-title":"Eur J Cancer"},{"key":"1027_CR147","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s41199-016-0015-8","volume":"1","author":"F Samim","year":"2016","unstructured":"Samim F, Epstein JB, Zumsteg ZS, Ho AS, Barasch A. Oral and dental health in head and neck cancer survivors. Cancers Head Neck. 2016;1:14. https:\/\/doi.org\/10.1186\/s41199-016-0015-8.","journal-title":"Cancers Head Neck"},{"key":"1027_CR148","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1002\/ijc.70033","volume":"157","author":"KJ Taylor","year":"2025","unstructured":"Taylor KJ, Amdal CD, Bjordal K, Astrup GL, Herlofson BB, Duprez F, et al. Toxicities in long-term survivors of head and neck cancer\u2014a multi-national cross-sectional analysis. Int J Cancer. 2025;157:2061\u201370. https:\/\/doi.org\/10.1002\/ijc.70033.","journal-title":"Int J Cancer"},{"key":"1027_CR149","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00520-019-04792-3","volume":"28","author":"LC Jardim","year":"2020","unstructured":"Jardim LC, Flores PT, do Carmo Dos Santos Ara\u00fajo M, Chiesa J, de Moraes CMB, Antoniazzi RP. Oral health-related quality of life in breast cancer survivors. Support Care Cancer. 2020;28:65\u201371. https:\/\/doi.org\/10.1007\/s00520-019-04792-3.","journal-title":"Support Care Cancer"},{"key":"1027_CR150","doi-asserted-by":"publisher","first-page":"4587","DOI":"10.1007\/s00520-019-04758-5","volume":"27","author":"JB Epstein","year":"2019","unstructured":"Epstein JB, de Andrade E Silva SM, Epstein GL, Leal JHS, Barasch A, Smutzer G. Taste disorders following cancer treatment: report of a case series. Support Care Cancer. 2019;27:4587\u201395. https:\/\/doi.org\/10.1007\/s00520-019-04758-5.","journal-title":"Support Care Cancer"},{"key":"1027_CR151","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-024-08688-9","volume":"32","author":"C Hong","year":"2024","unstructured":"Hong C, Jensen SB, Vissink A, Bonomo P, Santos-Silva AR, Gueiros LA, et al. MASCC\/ISOO Clinical practice statement: management of salivary gland hypofunction and xerostomia in cancer patients. Support Care Cancer. 2024;32:548. https:\/\/doi.org\/10.1007\/s00520-024-08688-9.","journal-title":"Support Care Cancer"},{"key":"1027_CR152","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s00520-017-3629-4","volume":"25","author":"E Vigarios","year":"2017","unstructured":"Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer. 2017;25:1713\u201339. https:\/\/doi.org\/10.1007\/s00520-017-3629-4.","journal-title":"Support Care Cancer"},{"key":"1027_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00098-1","volume":"26","author":"E Vigarios","year":"2025","unstructured":"Vigarios E, Warnakulasuriya S, Pomar P, Maret D. Integrating dental and oral care in oncology: a crucial step towards comprehensive cancer treatment. Lancet Oncol. 2025;26:e184. https:\/\/doi.org\/10.1016\/S1470-2045(25)00098-1.","journal-title":"Lancet Oncol"},{"key":"1027_CR154","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-024-08614-z","volume":"32","author":"LDS Ribeiro","year":"2024","unstructured":"Ribeiro LDS, Silveira RCDCP, Vasques CI, De Men\u00eases AG, Dos Reis PED, Ferreira EB. Hyaluronic acid to manage radiotoxicities in gynecological cancer patients: a scoping review. Support Care Cancer. 2024;32:439. https:\/\/doi.org\/10.1007\/s00520-024-08614-z.","journal-title":"Support Care Cancer"},{"key":"1027_CR155","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1159\/000496036","volume":"42","author":"P Delia","year":"2019","unstructured":"Delia P, Sansotta G, Pontoriero A, Iati G, De Salvo S, Pisana M, et al. Clinical evaluation of low-molecular-weight hyaluronic acid-based treatment on onset of acute side effects in women receiving adjuvant radiotherapy after cervical surgery: a randomized clinical trial. Oncol Res Treat. 2019;42:212\u20138. https:\/\/doi.org\/10.1159\/000496036.","journal-title":"Oncol Res Treat"},{"key":"1027_CR156","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.clbc.2025.08.001","volume":"25","author":"P Villa","year":"2025","unstructured":"Villa P, Cassani C, Nappi RE, Bounous VE, Franchi D, Guida M, et al. Quality of life and satisfaction with Ospemifene for treating vulvovaginal atrophy in breast cancer survivors: six-month results from the PatiEnt SatisfactiON StudY (PEONY). Clin Breast Cancer. 2025;25:782\u2013791.e2. https:\/\/doi.org\/10.1016\/j.clbc.2025.08.001.","journal-title":"Clin Breast Cancer"},{"key":"1027_CR157","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11051304","volume":"11","author":"A Wo\u017aniak","year":"2023","unstructured":"Wo\u017aniak A, Wo\u017aniak S, Poleszak E, Kluz T, Zapa\u0142a \u0141, Wo\u017aniak A, et al. Efficacy of fractional CO2 laser treatment for genitourinary syndrome of menopause in short-term evaluation\u2014preliminary study. Biomedicines. 2023;11:1304. https:\/\/doi.org\/10.3390\/biomedicines11051304.","journal-title":"Biomedicines"},{"key":"1027_CR158","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/13697137.2019.1646720","volume":"23","author":"S Athanasiou","year":"2020","unstructured":"Athanasiou S, Pitsouni E, Grigoriadis T, Michailidis G, Tsiveleka A, Rodolakis A, et al. A study protocol of vaginal laser therapy in gynecological cancer survivors. Climacteric. 2020;23:53\u20138. https:\/\/doi.org\/10.1080\/13697137.2019.1646720.","journal-title":"Climacteric"},{"key":"1027_CR159","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/jnci\/93.8.618","volume":"93","author":"JP Neglia","year":"2001","unstructured":"Neglia JP, Friedman DL, Yasui Y, Mertens AC, Hammond S, Stovall M, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst. 2001;93:618\u201329. https:\/\/doi.org\/10.1093\/jnci\/93.8.618.","journal-title":"J Natl Cancer Inst"},{"key":"1027_CR160","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-016-0738-z","volume":"12","author":"N-S Hegemann","year":"2017","unstructured":"Hegemann N-S, Schlesinger-Raab A, Ganswindt U, H\u00f6rl C, Combs SE, H\u00f6lzel D, et al. Risk of second cancer following radiotherapy for prostate cancer: a population-based analysis. Radiat Oncol. 2017;12:2. https:\/\/doi.org\/10.1186\/s13014-016-0738-z.","journal-title":"Radiat Oncol"},{"key":"1027_CR161","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1200\/JCO.2005.06.237","volume":"23","author":"JL Perkins","year":"2005","unstructured":"Perkins JL, Liu Y, Mitby PA, Neglia JP, Hammond S, Stovall M, et al. Nonmelanoma skin cancer in survivors of childhood and adolescent cancer: a report from the Childhood Cancer Survivor Study. JCO. 2005;23:3733\u201341. https:\/\/doi.org\/10.1200\/JCO.2005.06.237.","journal-title":"JCO"},{"key":"1027_CR162","doi-asserted-by":"publisher","unstructured":"Goldust M, Giulini M, Weidenthaler\u2010Barth B, Gupta M, Grabbe S, Schepler H. Increased risk of angiosarcoma secondary to cancer radiotherapy: case series and review of the treatment options. Dermatol Ther. 2020;33(2):e13234. https:\/\/doi.org\/10.1111\/dth.13234.","DOI":"10.1111\/dth.13234"},{"key":"1027_CR163","doi-asserted-by":"publisher","unstructured":"Cantisani C, Kiss N, Naqeshbandi AF, Tosti G, Tofani S, Cartoni C, et al. Nonmelanoma skin cancer associated with hydroxyurea treatment: overview of the literature and our own experience. Dermatol Ther. 2019;32(5):e13043. https:\/\/doi.org\/10.1111\/dth.13043.","DOI":"10.1111\/dth.13043"},{"key":"1027_CR164","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/s41416-023-02172-7","volume":"128","author":"S Polesie","year":"2023","unstructured":"Polesie S, Gillstedt M, Schmidt SAJ, Egeberg A, Potteg\u00e5rd A, Kristensen K. Use of methotrexate and risk of skin cancer: a nationwide case-control study. Br J Cancer. 2023;128:1311\u20139. https:\/\/doi.org\/10.1038\/s41416-023-02172-7.","journal-title":"Br J Cancer"},{"key":"1027_CR165","doi-asserted-by":"publisher","first-page":"16978","DOI":"10.7759\/cureus.16978","volume":"13","author":"DR Gavini","year":"2021","unstructured":"Gavini DR, Salvi DJ, Shah PH, Uma D, Lee JH, Hamid P. Non-melanoma skin cancers in patients on hydroxyurea for Philadelphia chromosome-negative myeloproliferative neoplasms. A systematic review. Cureus. 2021;13:16978. https:\/\/doi.org\/10.7759\/cureus.16978.","journal-title":"Cureus"},{"key":"1027_CR166","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jaad.2022.11.043","volume":"88","author":"MA Kreher","year":"2023","unstructured":"Kreher MA, Konda S, Noland MMB, Longo MI, Valdes-Rodriguez R. Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: methotrexate, alkylating agents, biologics, and small molecule inhibitors. J Am Acad Dermatol. 2023;88:534\u201342. https:\/\/doi.org\/10.1016\/j.jaad.2022.11.043.","journal-title":"J Am Acad Dermatol"},{"key":"1027_CR167","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jaad.2022.11.044","volume":"88","author":"MA Kreher","year":"2023","unstructured":"Kreher MA, Noland MMB, Konda S, Longo MI, Valdes-Rodriguez R. Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part I: calcineurin inhibitors, thiopurines, IMDH inhibitors, mTOR inhibitors, and corticosteroids. J Am Acad Dermatol. 2023;88:521\u201330. https:\/\/doi.org\/10.1016\/j.jaad.2022.11.044.","journal-title":"J Am Acad Dermatol"},{"key":"1027_CR168","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/bjh.17192","volume":"193","author":"N Polverelli","year":"2021","unstructured":"Polverelli N, Elli EM, Abruzzese E, Palumbo GA, Benevolo G, Tiribelli M, et al. Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Br J Haematol. 2021;193:356\u201368. https:\/\/doi.org\/10.1111\/bjh.17192.","journal-title":"Br J Haematol"},{"issue":"25","key":"1027_CR169","doi-asserted-by":"publisher","first-page":"02959","DOI":"10.1016\/j.jaad.2025.10.011","volume":"S0190\u20139622","author":"V Shah","year":"2025","unstructured":"Shah V, Nijhawan RI. Skin cancer risk in bone-marrow transplant patients treated with ruxolitinib compared with other immunosuppressive therapies. J Am Acad Dermatol. 2025;S0190\u20139622(25):02959\u201367. https:\/\/doi.org\/10.1016\/j.jaad.2025.10.011.","journal-title":"J Am Acad Dermatol"},{"key":"1027_CR170","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1182\/blood.2023022345","volume":"143","author":"A Rampotas","year":"2024","unstructured":"Rampotas A, Carter-Brzezinski L, Somervaille TCP, Forryan J, Panitsas F, Harrison C, et al. Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib. Blood. 2024;143:178\u201382. https:\/\/doi.org\/10.1182\/blood.2023022345.","journal-title":"Blood"},{"key":"1027_CR171","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1001\/jama.2013.6296","volume":"309","author":"MM Hudson","year":"2013","unstructured":"Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013;309:2371. https:\/\/doi.org\/10.1001\/jama.2013.6296.","journal-title":"JAMA"},{"key":"1027_CR172","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jaad.2013.10.034","volume":"70","author":"M Choi","year":"2014","unstructured":"Choi M, Kim MS, Park SY, Park GH, Jo SJ, Cho KH, et al. Clinical characteristics of chemotherapy-induced alopecia in childhood. J Am Acad Dermatol. 2014;70:499\u2013505. https:\/\/doi.org\/10.1016\/j.jaad.2013.10.034.","journal-title":"J Am Acad Dermatol"},{"key":"1027_CR173","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13950","volume":"33","author":"LR Lemes","year":"2020","unstructured":"Lemes LR, Melo DF, de Oliveira DS, de La-Rocque M, Zompero C, Ramos PM. Topical and oral minoxidil for hair disorders in pediatric patients: what do we know so far? Dermatol Ther. 2020;33:e13950. https:\/\/doi.org\/10.1111\/dth.13950.","journal-title":"Dermatol Ther"},{"key":"1027_CR174","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMsa060185","volume":"355","author":"KC Oeffinger","year":"2006","unstructured":"Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355:1572\u201382. https:\/\/doi.org\/10.1056\/NEJMsa060185.","journal-title":"N Engl J Med"},{"key":"1027_CR175","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/1043454206289756","volume":"23","author":"SS Larouche","year":"2006","unstructured":"Larouche SS, Chin-Peuckert L. Changes in body image experienced by adolescents with cancer. J Pediatr Oncol Nurs. 2006;23:200\u20139. https:\/\/doi.org\/10.1177\/1043454206289756.","journal-title":"J Pediatr Oncol Nurs"},{"key":"1027_CR176","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/pbc.20949","volume":"49","author":"PC Nathan","year":"2007","unstructured":"Nathan PC, Ness KK, Greenberg ML, Hudson M, Wolden S, Davidoff A, et al. Health-related quality of life in adult survivors of childhood Wilms tumor or neuroblastoma: a report from the childhood cancer survivor study. Pediatr Blood Cancer. 2007;49:704\u201315. https:\/\/doi.org\/10.1002\/pbc.20949.","journal-title":"Pediatr Blood Cancer"},{"key":"1027_CR177","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1200\/JCO.2004.06.148","volume":"22","author":"BJ Zebrack","year":"2004","unstructured":"Zebrack BJ, Gurney JG, Oeffinger K, Whitton J, Packer RJ, Mertens A, et al. Psychological outcomes in long-term survivors of childhood brain cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2004;22:999\u20131006. https:\/\/doi.org\/10.1200\/JCO.2004.06.148.","journal-title":"J Clin Oncol"},{"key":"1027_CR178","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/pon.4439","volume":"27","author":"SC Vuotto","year":"2018","unstructured":"Vuotto SC, Ojha RP, Li C, Kimberg C, Klosky JL, Krull KR, et al. The role of body image dissatisfaction in the association between treatment-related scarring or disfigurement and psychological distress in adult survivors of childhood cancer. Psychooncology. 2018;27:216\u201322. https:\/\/doi.org\/10.1002\/pon.4439.","journal-title":"Psychooncology"},{"key":"1027_CR179","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ejca.2005.08.042","volume":"42","author":"F Levi","year":"2006","unstructured":"Levi F, Moeckli R, Randimbison L, Te V-C, Maspoli M, La Vecchia C. Skin cancer in survivors of childhood and adolescent cancer. Eur J Cancer. 2006;42:656\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2005.08.042.","journal-title":"Eur J Cancer"},{"key":"1027_CR180","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1200\/JCO.2008.21.1425","volume":"27","author":"GT Armstrong","year":"2009","unstructured":"Armstrong GT, Liu Q, Yasui Y, Neglia JP, Leisenring W, Robison LL, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27:2328\u201338. https:\/\/doi.org\/10.1200\/JCO.2008.21.1425.","journal-title":"J Clin Oncol"},{"key":"1027_CR181","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1016\/j.jid.2019.02.033","volume":"139","author":"AC Geller","year":"2019","unstructured":"Geller AC, Keske RR, Haneuse S, Davine JA, Emmons KM, Daniel CL, et al. Skin cancer early detection practices among adult survivors of childhood cancer treated with radiation. J Invest Dermatol. 2019;139:1898\u20131905.e2. https:\/\/doi.org\/10.1016\/j.jid.2019.02.033.","journal-title":"J Invest Dermatol"},{"key":"1027_CR182","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1200\/JCO.2017.77.0180","volume":"36","author":"W Landier","year":"2018","unstructured":"Landier W, Skinner R, Wallace WH, Hjorth L, Mulder RL, Wong FL, et al. Surveillance for late effects in childhood cancer survivors. J Clin Oncol. 2018;36:2216\u201322. https:\/\/doi.org\/10.1200\/JCO.2017.77.0180.","journal-title":"J Clin Oncol"},{"issue":"163\u20137","key":"1027_CR183","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1080\/00325481.1990.11704531","volume":"87","author":"S Dreizen","year":"1990","unstructured":"Dreizen S, McCredie KB, Keating MJ, Andersson BS. Nutritional deficiencies in patients receiving cancer chemotherapy. Postgrad Med. 1990;87(163\u20137):170. https:\/\/doi.org\/10.1080\/00325481.1990.11704531.","journal-title":"Postgrad Med"},{"key":"1027_CR184","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25094773","volume":"25","author":"E Azzini","year":"2024","unstructured":"Azzini E, Furini T, Polito A, Scalfi L, Pinto A, Gasperi V, et al. Vitamin nutritional status in patients with pancreatic cancer: a narrative review. Int J Mol Sci. 2024;25:4773. https:\/\/doi.org\/10.3390\/ijms25094773.","journal-title":"Int J Mol Sci"},{"key":"1027_CR185","doi-asserted-by":"publisher","DOI":"10.3390\/nu15071731","volume":"15","author":"C Ogland-Hand","year":"2023","unstructured":"Ogland-Hand C, Ciesielski TH, Daunov K, Bean MK, Nock NL. Food insecurity and nutritional challenges in adolescent and young adult cancer survivors in the U.S.A.: a narrative review and call to action. Nutrients. 2023;15:1731. https:\/\/doi.org\/10.3390\/nu15071731.","journal-title":"Nutrients"},{"key":"1027_CR186","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22105145","volume":"22","author":"G Schepisi","year":"2021","unstructured":"Schepisi G, Gianni C, Bleve S, De Padova S, Menna C, Lolli C, et al. Vitamin D deficiency in testicular cancer survivors: a systematic review. Int J Mol Sci. 2021;22:5145. https:\/\/doi.org\/10.3390\/ijms22105145.","journal-title":"Int J Mol Sci"},{"key":"1027_CR187","doi-asserted-by":"publisher","DOI":"10.3390\/nu17203272","volume":"17","author":"M Osmola","year":"2025","unstructured":"Osmola M, Tyszka M, Jirka A, Ciepiela O, Kapa\u0142a A, Lenti MV, et al. Vitamin B12 in cancer patients: clinical insights into deficiency, excess, diagnosis, and management. Nutrients. 2025;17:3272. https:\/\/doi.org\/10.3390\/nu17203272.","journal-title":"Nutrients"},{"key":"1027_CR188","doi-asserted-by":"publisher","DOI":"10.3390\/nu15143239","volume":"15","author":"A Podpeskar","year":"2023","unstructured":"Podpeskar A, Crazzolara R, Kropshofer G, Hetzer B, Rabensteiner E, Meister B, et al. Recommendations for nutritional supplementation in pediatric oncology: a compilation of the facts. Nutrients. 2023;15:3239. https:\/\/doi.org\/10.3390\/nu15143239.","journal-title":"Nutrients"},{"key":"1027_CR189","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3949\/ccjm.83a.15061","volume":"83","author":"F Galimberti","year":"2016","unstructured":"Galimberti F, Mesinkovska NA. Skin findings associated with nutritional deficiencies. Cleve Clin J Med. 2016;83:731\u20139. https:\/\/doi.org\/10.3949\/ccjm.83a.15061.","journal-title":"Cleve Clin J Med"},{"key":"1027_CR190","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/ncp.10321","volume":"34","author":"M DiBaise","year":"2019","unstructured":"DiBaise M, Tarleton SM. Hair, nails, and skin: differentiating cutaneous manifestations of micronutrient deficiency. Nutr Clin Pract. 2019;34:490\u2013503. https:\/\/doi.org\/10.1002\/ncp.10321.","journal-title":"Nutr Clin Pract"},{"key":"1027_CR191","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-024-01666-4","author":"SY Tan","year":"2024","unstructured":"Tan SY, Tsoukalas T, Javier K, Fazon T, Singh S, Vardy J. Recommendations on the surveillance and supplementation of vitamins and minerals for upper gastrointestinal cancer survivors: a scoping review. J Cancer Surviv. 2024. https:\/\/doi.org\/10.1007\/s11764-024-01666-4.","journal-title":"J Cancer Surviv"},{"key":"1027_CR192","doi-asserted-by":"publisher","unstructured":"Harvie M. Nutritional supplements and cancer: potential benefits and proven harms. Am Soc Clin Oncol Educ Book. 2014;e478\u201386. https:\/\/doi.org\/10.14694\/EdBook_AM.2014.34.e478. PMID: 24857143","DOI":"10.14694\/EdBook_AM.2014.34.e478"},{"key":"1027_CR193","doi-asserted-by":"publisher","DOI":"10.3390\/nu17091451","volume":"17","author":"A Sechi","year":"2025","unstructured":"Sechi A, Cedirian S, Brunetti T, Quadrelli F, Torres F, Tosti A, et al. Safety first: a comprehensive review of nutritional supplements for hair loss in breast cancer patients. Nutrients. 2025;17:1451. https:\/\/doi.org\/10.3390\/nu17091451.","journal-title":"Nutrients"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01027-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01027-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01027-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:42:53Z","timestamp":1778661773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-026-01027-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":193,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1027"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01027-0","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Luca Rapparini, Timila Assia Touhouche, Davide Fattore, Azael Freites-Martinez, Pauline Hirtz, Zoe Apalla, Emmanuelle Vigarios, Delphine Maret, Michela Starace, and Vincent Sibaud declare that they have no conflicts of interest that might be relevant to the contents of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The patients, or patient\u2019s parents\/guardians, in this article have given written informed consent for the publication of their photos, according to the Declaration of Helsinki principles.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"No datasets were generated or analyzed during the current study. A review of the literature was conducted using previously published data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the conception and drafting of the manuscript and provided clinical images. All authors critically revised the manuscript for important intellectual content and approved the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}